NIH Office of Technology Transfer (OTT)


	Compounds Binding to the N-Terminal Domains of STAT Proteins as Therapeutic Agents Signal transducer and activator transcription (STAT) proteins, specifically STAT1, 2, 3, 4, 5a, 5b, and 6, are involved in the cellular and biological processes of cell proliferation, differentiation, apoptosis, host defense, and transformation. Constitutively active STAT proteins occur in many human tumor cells and cells transformed by oncoproteins. Inhibiting these STAT proteins has great therapeutic potential in the treatment of certain cancers. The current invention describes a family of short peptides that bind to the N-terminus domains of STAT proteins and their use as therapeutic agents. These compounds are the first inhibitors that can directly bind to N-domains of STATs and exhibit a direct inhibitory effect. STAT1, 3, and 5 inhibitors can serve as potent therapeutic agents for the treatment of a variety of tumors and STAT 4 inhibitors can be used to control autoimmune disorders. More... View Featured Influenza Vaccine and Diagnostic Technologies View Monthly Featured Technologies

Cooperative Research & Development Agreements from the National Institutes of Health Featured In Licensing Executives Society International Journal Series

Cooperative Research Development Agreements (CRADAs) from the National Institutes of Health (NIH) and the Department of Energy are the focus of a new series of articles published in les Nouvelles, the Journal of the Licensing Executive Society International (LESI). A two part series entitled “Intellectual Property and Other Issues in Cooperative Research and Development Agreements (CRADAs)” appears in the March and June issues of the journal published by LESI, an association of 32 national and regional societies who are engaged in the profession of licensing and other aspects of transferring or developing intellectual property.

Co-authored by Matthew W. Sagal, Senior Manager of the Alliance Management Group, Gene Slowinski, Director of Strategic Alliance Research at Rutgers University, Kenneth B. Freese, Manager of Intellectual Asset Strategies at the Los Alamos National Laboratories and Steven M. Ferguson, Deputy Director of Licensing & Entrepreneurship at the NIH Office of Technology Transfer, the article series highlights patent licensing for new inventions arising from CRADA collaborations between companies and these two federal laboratories. Individual CRADA licensing case studies such as “Alliance for Advanced Energy Solutions” (Los Alamos) and “Developing Velcade® for Treatment of Multiple Myeloma” (NIH) are also included.

Interested parties can read the March issue or obtain specific information about starting their own CRADA collaboration with at NIH here.

Recently Archived Issues

	About NIH OTT \| Licensing & Royalties \| CRADAs & MTAs \| Forms & Model Agreements \| Policy \| FAQs \| Contact Us For NIH Staff only \| Site Map \| FOIA \| Privacy Notice \| Disclaimers \| Accessibility
	Office of Technology Transfer (OTT)		National Institutes of Health (NIH)		Department of Health and Human Services (HHS)

Note that this site uses cookies, Click here for more information.